Oct, 2024

Global
News / Press Releases
Astellas to Present VEOZATM (fezolinetant) Data at IMS World Congress on Menopause
TOKYO, October 10, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that VEOZA TM (fezolinetant) * , its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be featured in four oral and two poster presentations during the International Menopause Society (IMS) 19 th World Congress on Menopause in...
Read More
Global
News / Press Releases
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
- Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development - - AviadoBio receives $20 million equity investment, up to $30 million in upfront payments and is eligible to receive up to $2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option - LONDON, and TOKYO, - Oct 8, 2024 – AviadoBio...
Read More
Global
News / General News
Integrated Report 2024 is now available.
Read More
Global
News / Stories
Leading the Charge in Oncology: How Astellas is Redefining Cancer Treatment
Read More

Sep, 2024

Global
News / Press Releases
Japan’s Ministry of Health, Labour and Welfare Approves PADCEVTM (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing chemotherapy, the current standard of care for first-line treatment of radically unresectable urothelial carcinoma 1 - - Approval follows priority review designation from the Ministry of Health, Labour and...
Read More

Oct, 2024

Global
News / Press Releases
Astellas to Present VEOZATM (fezolinetant) Data at IMS World Congress on Menopause
TOKYO, October 10, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that VEOZA TM (fezolinetant) * , its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be featured in four oral and two poster presentations during the International Menopause Society (IMS) 19 th World Congress on Menopause in...
Read More
Global
News / Press Releases
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
- Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development - - AviadoBio receives $20 million equity investment, up to $30 million in upfront payments and is eligible to receive up to $2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option - LONDON, and TOKYO, - Oct 8, 2024 – AviadoBio...
Read More

Sep, 2024

Global
News / Press Releases
Japan’s Ministry of Health, Labour and Welfare Approves PADCEVTM (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma
- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing chemotherapy, the current standard of care for first-line treatment of radically unresectable urothelial carcinoma 1 - - Approval follows priority review designation from the Ministry of Health, Labour and...
Read More
Global
News / Press Releases
Astellas Receives Approval from the European Commission for VYLOYTM (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer
- Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer 1,2 - - Treatment with the claudin 18.2-targeted monoclonal antibody shown to significantly extend both progression-free survival and overall survival in Phase 3 trials 1,2 - TOKYO, 20 September, 2024 –...
Read More
Global
News / Press Releases
Astellas Announces FDA Listing of DIGITIVA™ for the Management of Heart Failure
TOKYO, September 18, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that DIGITIVA™, a non-invasive digital health solution for heart failure management, has been listed with the U.S. Food and Drug Administration (FDA). DIGITIVA is classified as a Class I Software as a Medical Device (SaMD) and is exempt from 510(k) premarket submission*...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match.

Back to Newsroom